McKesson Corporation

- In early April, McKesson established an independent capital structure for its Medical Surgical Solutions segment by issuing a $1 billion revolving credit facility and $1 billion in Term Loan A facilities. - McKesson plans to issue up to $2.25 billion in additional term loans in the second half of the first quarter of fiscal 2027 to support the Medical Surgical Solutions separation. - Apollo Funds is acquiring approximately a 13% minority interest in Medical Surgical Solutions through a $1.25 billion strategic investment, valuing the business at around $13 billion. - These financing transactions will be used primarily to satisfy existing intercompany agreements and support the separation readiness and financial flexibility of the Medical Surgical Solutions business. - The proceeds from these financings are intended to be deployed mainly toward share repurchases in line with McKesson’s capital allocation strategy.

- Fiscal 2026 capital expenditures totaled $745 million, focusing on distribution technology and infrastructure to support future growth. - Investments continue to advance technology-enabled services, enhancing product functionality, customer experience, and automation. - Launch of a state-of-the-art Montreal distribution center featuring AI-powered storage/retrieval systems to expand capacity and improve resiliency. - Implementation of AI-driven inventory planning systems for end-to-end real-time decision making, contributing to working capital savings. - Ongoing investments in operational efficiency and infrastructure improvements to drive long-term growth in North American Pharmaceutical segment. - Continued deployment of technology in Oncology and Multispecialty segments, including ambient scribe technology and automation to improve provider productivity. - Planned issuance of up to $2.25 billion in additional term loans to support Medical Surgical Solutions separation, facilitating disciplined capital allocation including share repurchases. - Focus on innovation and efficiency in Corporate (~$580M to $640M expenses) including technology investments to support business transformation.

- Overall revenue growth for fiscal 2027 is guided at 5% to 9%, with adjusted operating profit growth of 8% to 12%. - North American Pharmaceutical segment: revenue expected to increase 4% to 8%, supported by stable prescription volume growth and specialty product distribution, including GLP-1 category growth. - Oncology and Multispecialty segment: strong revenue growth anticipated, 14.5% to 18.5%, driven by expanded provider networks, acquisitions (PRISM and Core Ventures), and increased specialty distribution volumes. - Prescription Technology Solutions segment: revenue growth of 2.5% to 6.5%, with demand strong for access and affordability solutions, particularly specialty therapies. - Stable utilization trends expected, with specialty prescriptions and innovative therapies driving growth. - Continued growth anticipated in GLP-1 medications with quarter-to-quarter variability. - Investment in technology and operational efficiencies underpin growth outlook.

- Fiscal 2027 adjusted earnings per diluted share (EPS) guidance range: $43.80 to $44.60, representing 12% to 14% year-over-year growth. - Excluding certain gains in fiscal 2026, fiscal 2027 EPS growth is 14% to 16%, at the upper end of the long-term target range. - Long-term adjusted earnings per diluted share growth target: 13% to 16%. - Long-term adjusted segment operating profit growth targets: - North American Pharmaceutical: 5% to 8% - Oncology and Multi-specialty: 13% to 16% - Prescription Technology Solutions: 10% to 13% - Fiscal 2027 revenue growth anticipated at 5% to 9%, with adjusted operating profit growth at 8% to 12%. - Continued growth driven by specialty pharmaceutical distribution, oncology platforms, technology services, and operational efficiencies.

The provided pages of the McKesson earnings call transcript do not explicitly mention details about the current or expected order book or pending orders. However, from the discussion, the following points are noted that indirectly relate to business momentum and growth outlook: - Strong business momentum with specialty pharmaceutical distribution growth, oncology and multispecialty expansion. - Revenue growth guidance for fiscal 2027: 5% to 9% overall, 1% to 6% for Medical Surgical Solutions. - Continued provider expansion with more than 570 new providers added in the U.S. oncology network in fiscal ’26. - Ongoing growth in biopharma services, supporting 3.4 million patients in the latest season. - Technology-enabled services and automation are driving efficiency and growth. - No specific numeric data on orderbook or pending orders provided in the available pages. For precise current or expected order book figures, further detailed financial disclosures or investor reports would be necessary.